StreetAlpha.app
Home › Stocks › SGMT

Sagimet Biosciences Inc. (SGMT)

Healthcare
$9.08
▼ −5.61%
LAST CLOSE · NOV 20

Sagimet Biosciences develops FASN inhibitor drugs, led by denifanstat, for liver disease, acne and certain cancers. It last closed at $9.08 on Nov 20, down 5.61% on the day. The next earnings report for SGMT is expected around Wed, Mar 10, 2027. For the quarter ended Sep 2026, SGMT reported EPS of -$0.31. Over its last 8 reports the stock moved an average of 8.4% the session after earnings. Over the last 12 months SGMT insiders bought $0 of stock on the open market and sold $4.9M, according to SEC Form 4 filings.

AI Auto Pilots
Is SGMT in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold SGMT.

Key Stats

Last 12 months
Results
Net income
−$53.3M
EPS (diluted)
−$1.18
Balance sheet
Cash & equivalents
$111.0M
At Sep 30
Shareholder equity
$242.2M
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2022: −$30.5M−$30.5MFY2022FY2023: −$27.9M−$27.9MFY2023FY2024: −$45.6M−$45.6MFY2024FY2025: −$51.0M−$51.0MFY2025

From SGMT's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Next report
Mar 10
Estimated date · Time not announced
Reported EPS
-$0.31
Quarter ended Sep 2026
Year ago EPS
-$0.40
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.50Dec '24Mar 2025: -$0.56Mar '25Jun 2025: -$0.32Jun '25Sep 2025: -$0.40Sep '25Dec 2025: -$0.30Dec '25Mar 2026: -$0.33Mar '26Jun 2026: -$0.26Jun '26Sep 2026: -$0.31Sep '26Latest -$0.31
Revenue by quarter
Not enough quarters on file yet.
How SGMT moved after its last 8 reports
Average move the session after a report ±8.4%
Nov 12, 2026Time not announced−4.2%
Aug 11, 2026Time not announced−0.5%
Apr 27, 2026Time not announced+38.6%
Mar 11, 2026Time not announced+3.8%
Nov 13, 2025Time not announced−12.2%
Aug 13, 2025Time not announced+0.3%
May 8, 2025Time not announced−4.2%
Mar 12, 2025Time not announced+3.4%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on SGMTStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on SGMT
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on SGMT

Technical Analysis

SGMT · as of the Nov 20 close · updated each morning
Pullback inside a longer uptrend

The stock is 12% below its 20 day and 8% below its 50 day average. It is 14% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 42). The nearest support is the swing low (Aug 14) at $9.07, and the nearest resistance the Pivot at $9.10.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNormal
VolatilityNormal, 7.5%/day
Key levels
$11.4552 week high+26.1%
$10.1420 day average+11.7%
$9.7750 day average+7.6%
$9.38Pivot R1+3.3%
$9.35100 day average+3.0%
$9.15Swing high (Oct 12)+0.8%
$9.10Pivot+0.2%
$9.08Last close
$9.07Swing low (Aug 14)−0.1%
$8.81Pivot S1−3.0%
$7.80200 day average−14.1%
$4.5052 week low−50.4%
Indicators
RSI (14)42.27Middle of its rangeNeutral
MACD0.04Below its signal lineBearish
Stochastic26.4Middle of its rangeNeutral
ADX (14)17.8No clear trend
Williams %R-90.5Oversold below −80, overbought above −20Oversold
CCI (20)-164.5Oversold below −100, overbought above 100Oversold
Rate of change−7.8%Change over 10 sessionsBearish
ATR (14)$0.68Typical daily range, 7.5% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
What happened before, for SGMT

What happened before

See how SGMT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow SGMT usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How SGMT has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2023.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for SGMTHow many large options trades hit SGMT, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

SGMT Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲107 buying vs 43 selling
  • ▲Shares held by funds +36.7%
  • ▲Funds holding +32
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding154122+26.2%
In funds' top 1030–
Held by funds–––
New / increased50 / 5757 / 36+15.1%
Reduced / sold out23 / 2010 / 24+26.5%
Put/call ratio11.31––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See SGMT institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

SGMT Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$4.9M10 sales · 5 insiders
86% of the selling was under pre-arranged trading plans.
2026-02 sold $105K2026-07 sold $719K2026-08 sold $3.8MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Aug 14George KembleDirectorSale plan350,987$10.23$3.6M
Aug 11George KembleDirectorSale plan20,206$9.95$201K
Jul 20George KembleDirectorSale plan18,844$7.46$141K
Jul 20Elizabeth RozekChief Legal & Admin. OfficerSale10,545$7.76$82K
Jul 20David HappelPresident & CEOSale64,051$7.76$497K
Feb 10Elizabeth RozekChief Legal & Admin. OfficerSale2,622$5.36$14K
Every insider buy and sale for SGMT over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See SGMT insider trades →

From SEC Form 4 filings by SGMT's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SGMT is in one of them and how their past SGMT trades turned out.

SGMT in the AI portfolios
Loading…

SGMT News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered SGMT in an article yet. Here's the latest on the wider market.

SGMT in the news

About Sagimet Biosciences

Sagimet Biosciences is a biopharmaceutical company based in Foster City, California, that develops drugs called FASN inhibitors. Its lead candidate, denifanstat, is a pill taken by mouth once a day that is being studied for MASH, a serious form of fatty liver disease, along with acne and certain cancers. A second candidate, TVB-3567, is in early human testing for acne. The company aims these medicines at patients with metabolic and liver conditions, and a licensee in China is developing denifanstat for acne.

Headquarters
Foster City, CA